Tyra Biosciences Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +22.9% | +19.6% | +3.3% | +0.8% | +13.4% | -0.7% | -2.1% | -6.4% | +0.8% | +4.5% | +0.0% | – | |
| – | -4.4% | -1.7% | +7.2% | +71.7% | -11.5% | -4.2% | -0.7% | +18.8% | +0.7% | +2.9% | +30.4% | – | |
| – | – | -209.4% | – | -99.6% | +1,282.6% | -1,046.5% | – | – | +1,195.0% | -146.0% | – | – | |
| – | +626.5% | -77.4% | +245.6% | -88.9% | -88.5% | +133.3% | +121.4% | +25.8% | +46.2% | +54.4% | -25.0% | – | |
| – | +173,921.7% | – | -902.3% | – | -67.7% | +360.3% | -34.8% | -171.0% | – | -449.8% | – | – | |
| – | – | – | +48.5% | – | -100.0% | – | – | – | – | – | – | – | |
| – | -30.6% | +61,725.6% | -99.8% | +99.2% | -5.0% | +209.8% | -73.3% | +11.0% | +623.8% | +3,324.8% | -98.7% | – | |
| – | – | – | -178.9% | – | -370.9% | – | -125.5% | – | – | -51.0% | -246.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.